ISLAMABAD: A Russian pharmaceutical company has committed to invest around $80 million in Pakistan’s pharmaceutical sector over six years, with plans to establish local insulin manufacturing facilities under regulatory conditions set by the Drug Regulatory Authority of Pakistan, Business Recorder reported.
The regulator has approved maximum retail prices for six insulin products of M/s Genetics Pharmaceuticals and M/s Zavod Medsintez LLC, subject to the condition that the company begins work on local manufacturing and completes it by December 2031.
Under the plan, the investment will be carried out in two phases. The first phase involves setting up an aseptic filling plant with an estimated cost of $20 million, to be completed by December 2028. This facility will handle bulk imports and filling of insulin products.
The second phase includes the construction of an active pharmaceutical ingredient (API) production plant, with an estimated investment of $60 million. This facility will cover the full production process, from purification to packaging of insulin products, and is scheduled for completion by December 2031.
The regulator has directed the company to submit detailed timelines for each phase and stated that progress will be monitored. Non-compliance with the commitment to establish local manufacturing could result in cancellation of product registration.
The approved products include insulin formulations such as Rosinsulin C 100IU/ml, which will be imported initially and later produced locally once facilities are operational.
Officials said the move aims to support local production of essential medicines and reduce reliance on imports through phased investment and technology transfer.
